Biologics have become the first-line drugs in the treatment of moderate to severe inflammatory bowel disease (IBD) , and anti-tumor necrosis factor-α (TNF-α) monoclonal antibodies are widely used now. However, during the course of treatment, patients′ primary non-response and secondary failure often occur. This article mainly reviews some related biomarkers from the perspectives of genetics, cytokines, intestinal microbiome and routine laboratory indicators to predict the response of anti-TNF-α monoclonal antibodies, and then monitor the efficacy of drugs to help the clinicians to switch the treatment and optimize the therapeutic schedule in time.

Biologics have become the first-line drugs in the treatment of moderate to severe inflammatory bowel disease (IBD) , and anti-tumor necrosis factor-α (TNF-α) monoclonal antibodies are widely used now. However, during the course of treatment, patients′ primary non-response and secondary failure often occur. This article mainly reviews some related biomarkers from the perspectives of genetics, cytokines, intestinal microbiome and routine laboratory indicators to predict the response of anti-TNF-α monoclonal antibodies, and then monitor the efficacy of drugs to help the clinicians to switch the treatment and optimize the therapeutic schedule in time.